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Background: Inﬂuenza is associated with a high mortality and morbidity in older adults. Vaccination
remains the most effective method of preventing inﬂuenza and its consequences, however, vaccine
effectiveness decreaseswith increasing age and increasing immunosenescence. In older adults, immuno-
genicity studies suggest an MF59 adjuvanted inﬂuenza vaccine (ATIV, Fluad®) may help.
Methods: We evaluated the comparative effectiveness of ATIV, and unadjuvanted trivalent inﬂuenza vac-
cine (TIV) in reducing laboratory conﬁrmed inﬂuenza in the elderly. Elderly in three health authorities
duringwinter 2011–12were included in a community based case control study design. Cases tested posi-
tive and controls tested negative for inﬂuenza. Subjectswith known immunosuppressionwere excluded.
Logistic regression was used to calculate the odds ratio of vaccination (vs. no vaccination) in cases and
controls. ATIV and TIV effectiveness was described.
Results: A total of 282 eligible participants were enrolled (84 cases). Almost half (136) were in a long
term care facility and were 85 years of age or older (132) vaccine effectiveness decreased with increasing
age. In a variety of multivariate analyses, ATIV was signiﬁcantly protective at around 60% (p=0.02), with
only residence in long term care and health authority also signiﬁcant. Vaccine effectiveness increased in
non-long term care residents. In multivariate analyses TIV was ineffective.
Conclusion: An MF59 adjuvanted vaccine provided signiﬁcantly improved protection against inﬂuenza in
the elderly.
. Introduction
Inﬂuenza is associatedwith substantialmorbidity andmortality
specially in older adults. Each year an average of 20,000 hos-
italizations and between 2000 and 8000 deaths are attributed
o inﬂuenza and pneumonia in Canada, the eighth leading cause
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of death [1,2]. Increasing age, particularly over 70 years, brings
further increases in the risk of all-cause mortality or hospital-
ization with inﬂuenza or pneumonia [3]. In addition to causing
deaths from acute inﬂuenza illness and secondary bacterial pneu-
monia, inﬂuenzahasbeenassociatedwith increasedmortality from
ischaemic heart disease, cerebrovascular disease, and diabetes [4].
Up to90%of inﬂuenza-relateddeathsoccur inpersonsaged65years
or older [2].
Vaccination remains the most effective method of preventing
inﬂuenza virus infection and its sequellae [5]. However, vac-
cine effectiveness may be only 60% in healthy adult groups [6]
and effectiveness decreases with increasing age and increasing
immunosenecence. In older adults, seasons with signiﬁcant vac-
cine/virusmismatchhavebeen associatedwithdecreased antibody
response [7] and lack of vaccine effectiveness [8]. Enhanced vac-
cines are hence needed to provide adequate protection in the
elderly, particularly in mis-matched years.
A number of immunogenicity studies have shown superiority
of ATIV, a two-component vaccine consisting of three inﬂuenza
immunizing antigens, with an MF59 oil in water adjuvant (ATIV),
reserved.
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gainst unadjuvanted split virus and subunit trivalent inﬂuenza
accines (TIV) [9]. While these have varied in the extent (and
resence) of superiority in different studies and against differ-
nt inﬂuenza strains, the overall picture has been for improved
mmunogenicity.
The aim of this study was to evaluate, using a prospective
ommunity based case–control design in the elderly, the rel-
tive vaccine effectiveness against microbiologically conﬁrmed
nﬂuenza illness of ATIV and TIV, in comparison to no vaccination.
. Methods
In British Columbia all elderly over the age of 65 years are enti-
led to free inﬂuenza vaccine. In the 2011–12 season a combination
f standard TIV and adjuvanted vaccines licensed in Canada for use
n the elderly were available. All vaccines contained the recom-
ended strains for the Northern Hemisphere that year, antigens
rom anA/California/7/2009 (H1N1)-like virus, an A/Perth/16/2009
H3N2)-like virus and a B/Brisbane/60/2008-like virus.
In two health authorities, Fraser Health Authority (FHA) and
ancouver Coastal Health Authority (VCH), elderly residents over
5 years and all those in long termcare facilitieswere preferentially
ivenFluad® a trivalent, surface antigen, inactivated inﬂuenzavirus
accine, adjuvanted with MF59C.1. The MF59C.1 adjuvant con-
ained in ATIV is an oil-in-water emulsion composed of squalene as
heoil phase, stabilizedwith the surfactants polysorbate80and sor-
itantrioleate, in citrate. On Vancouver Island (VIHA) residents in
ong term care were offered ATIV, but all other elderly were offered
tandard TIV predominantly Fluviral® (GSK), a trivalent split virion
nﬂuenza vaccine.
The decision aboutwhich vaccine to usewasmade by the health
uthorities independent of the discussions to study the impact of
hese decisions. Due to shortages of certain vaccine brands at some
tages, some people aged 65–75 years in FHA and VCH were vacci-
ated with ATIV although the initial study design excluded this age
roup.
Apart from two hospital sites, all inﬂuenza tests in the three
ealth authorities are transferred to a central provincial labora-
ory. Primary care practitioners in the three health authoritieswere
ent ﬂocked Dacron swabs before the start of the inﬂuenza season
nd asked to take nasopharyngeal swabs from thosewith inﬂuenza
ike illness (ILI), inoculate them in viral transport media (VTM) and
ransport them to the central laboratory.
Testing of individuals was performed as part of routine clinical
are. Testing was performed at the BCCDC Public Health Micro-
iology and Reference Laboratory located at the BC Centre for
isease Control using a validated fourplex PCR assay for the detec-
ion of Inﬂuenza A and B and respiratory syncytial virus based
n the methods of Chen et al. [10]. The assay simultaneously tar-
ets the Inﬂuenza A, M gene, the Inﬂuenza B, NP gene and the
espiratory Syncytial Virus, L gene as well as RnaseP which is a
ousekeeping gene to ensure sample, extraction and ampliﬁcation
ntegrity. Nasopharyngeal swabs were collected from patients and
laced in viral transport media. After vortexing, 200l of sample
as extracted using a MagMAXTM Express-96 Deep Well Mag-
etic Particle Processor (Applied Biosystems®, Canada) yielding an
lution volume of 60l. Nucleic ampliﬁcation was performed on
n Applied Biosystems 7500 Fast Real-Time PCR System (Applied
iosystems®, Canada) using 5l of eluate. The lower limit of detec-
ion for each of the three viruses is between 10 and 100 copies.
nﬂuenza A reactive specimens were also typed using type speciﬁc
rimers targeting the HA gene as per Chen et al. and/or underwent
A gene sequencing.
The study received ethics approval from the Research Ethics
ommittees ofVancouverCoastal andFraserHealthAuthorities ande 31 (2013) 6122–6128 6123
theUniversity of British Columbia Ethics Committee. The studywas
registered with ClinicalTrials.gov (NCT01424371).
Commencing on December 12th, the ﬁrst day when more than
one positive sample in a week occurred, we selected all adults over
65 years of age who were tested for inﬂuenza. The study continued
until April 2nd, which represented the last positive inﬂuenza case
of the season for the study population.
Participants were included if they were 65 or older as of the
inﬂuenza test date, had inﬂuenza like symptoms (ILI) and were
swabbed and tested for inﬂuenza, and had no immunodeﬁciency
conditions. Additionally, patients testedmore than sevendays after
commencement of ILI were excluded.
Participants were classiﬁed as cases if the respiratory sample
was inﬂuenza positive. They were classiﬁed as a control if the test
was negative and they met a clinical case deﬁnition of inﬂuenza-
like-illness. Information on age, sex, hospitalization, residence in a
long term care facility, immune-suppression, and coexisting medi-
cal conditionswas collected by direct telephone interviewwith the
study participant or their caregiver. We also conﬁrmed the diag-
nosis of an inﬂuenza-like-illness through self-report or review of
long term care records. The vaccination status and date and type of
vaccination were conﬁrmed through the records of the healthcare
practitioner. Interviewers were not blinded to the status of cases
or controls. The same central interviewers were used in all three
health authorities.
Study participants were classiﬁed as vaccinated if they had
received a dose of the inﬂuenza vaccine at least 14 days before
the onset of symptoms and as ‘not vaccinated’, if they received no
vaccination or received the ﬁrst dose within 14 days of onset of
symptoms.
Data were entered and analyzed using SPSS for Windows, ver-
sion17.0.A statistical signiﬁcance level of0.05wasadopted. Testing
by the Chi-square analysis, Fishers exact test or t-tests was used
to assess the signiﬁcant differences in characteristics between
cases and controls, and between vaccinated and unvaccinated indi-
viduals. Odds ratios were calculated using laboratory conﬁrmed
inﬂuenza as the primary outcome and vaccination status as the
primary exposure. VE was calculated as one minus the odds ratio
based on the formula by Greenwood and Yule [11].
The primary outcome of interest was testing positive for
inﬂuenza. The independent factors assessed included sex, vaccine
type (ATIV or TIV), age group, long term care residency (LTCF), and
the presence of chronic disease. Participants who reported a date
and brand of inﬂuenza vaccine were recorded as vaccinated, and
those reporting not being vaccinated were recorded as such. Thus
inﬂuenza vaccination was treated as a dichotomous variable, and
any cases or controls that reported an unknown vaccination status
were excluded. Age, determined at the time of testing, was catego-
rized into <75, 75–84, and 85 years in addition to being treated as
a continuous variable. Chronic disease was based on one or more
of self-reported chronic cardiac, respiratory or neurological condi-
tions. Sex and long-term care residency at the time of testing were
also treated as dichotomous variables. Information onweek of test-
ing andhealth authority residencewas used to control for inﬂuenza
exposure.
To estimate the association between potential dependent (i.e.
predictor) variables and the outcome (i.e. testing positive for
inﬂuenza) we used logistic regression models. All univariate vari-
ables with a p<0.25, deemed to be potential confounders, or
thought to be a potentially useful predictors were included in
the multivariate model. Variables, which provided little predictive
power, were excluded. Variables were assessed for multicollinear-
ity, effect modiﬁers and confounders.
Subgroup analyses were conducted into more homogenous
strata that might reduce the effect of residual confounders or
bias and to explore vaccine effectiveness (VE). Subgroups included
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Fig. 2. Inﬂuenza epidemic curve for the three participating health authorities for
the 2011/12 inﬂuenza season (n=153). *Based on date of sample collection.
Source: Public Health Microbiology & Reference Laboratory. BC CDC.
Fig. 3. Count of study participants, by status and onset of symptoms (n=282). *Epi
week assigned based on onset of symptoms, not date of sample collection.
Table 1
Characteristics of study population.
ATIV (n=165) TIV (n=62) Unvaccinated
(n=55)
Health authority
Fraser 78 47.3 9 14.5 17 30.9
Vancouver coastal 69 41.8 16 25.8 21 38.2
Vancouver island 18 10.9 37 59.7 17 30.9
Long term care facility
Yes 127 77.0 18 29.0 15 27.3
No 38 23.0 44 71.0 40 72.7
Gender
Males 46 27.9 24 38.7 29 52.7
Females 119 72.1 38 61.3 26 47.3
Age groups
<75 13 7.9 22 35.5 17 30.9
75–84 56 33.9 23 37.1 19 34.5
85+ 96 58.2 17 27.4 19 34.5
Chronic disease
Yes 145 87.9 58 93.5 47 85.5
No 20 12.1 4 6.5 8 14.5
Respiratory chronic condition
Yes 46 27.9 21 33.9 18 32.7
No 119 72.1 41 66.1 37 67.3
Cardiac chronic condition
Yes 118 71.5 49 79.0 36 65.5
No 47 28.5 13 21.0 19 34.5
Neurological chronic condition
Yes 83 50.3 14 22.6 13 23.6
No 82 49.7 48 77.4 42 76.4
Hospitalized
Yes 27 16.4 31 50.0 25 45.5Fig. 1. Characteristics of study selection.
ong-term and non-long-term care residents. In order to perform a
irect comparison between TIV and ATIV, a relative vaccine effec-
iveness analysis was performed on only those study participants
accinated.
. Results
.1. Participants
The reviewperiod commencedonDecember 12th 2011, theﬁrst
ate on which more than one positive case in a week occurred. A
otal of 461 inﬂuenza tests were performed from then until April
nd when cases ceased. Of these, 17 cases were deceased and
nother 86 cases were unable to be contacted leaving 358 available
or recruitment. Of those contactable, 28 were ineligible as they
ad no ILI, 18 were ineligible as they were immune-suppressed,
5 had insufﬁcient English or incomplete information and 5 more
eclined to participate, leaving a total of 282 available partici-
ants (79%) enrolled in the study, 84 cases and 198 controls (see
ig. 1).
Inﬂuenza cases were not uniformly distributed over time
hrough the health authorities. The inﬂuenza epidemic curve for
he season in the three health authorities is shown in Fig. 2 (includ-
ng cases not in the target range) and the distribution over time of
ases and controls in the study shown in Fig. 3.
Participants’ demographic characteristics are presented in
able 1. The mean age of the sample was 83.0 years (standard
rror, 0.51) and almost one half were 85 years or older. The major-
ty of participants were females (186, 66%), residents of long term
are facilities (160, 57%), and reported at least one chronic disease
250, 89%). Themost commonly reportedchronicdisease categories
ere cardiac (203, 72%) followed by neurological (110, 39%) and
espiratory condition (85, 30%). One third of cases (30%) were hos-
italized for their ILI symptoms. A total of 227 (81%) subjects were
accinated against the inﬂuenza, and among those vaccinated, 73%
ere vaccinated with ATIV compared to 27% who were vaccinated
ith TIV. Inﬂuenza subtyping was done for the 84 cases, of which
No 138 83.6 31 50.0 30 54.5
Inﬂuenza
Yes 42 25.5 23 37.1 19 34.5
No 123 74.5 39 62.9 36 65.5
P.G. Van Buynder et al. / Vaccine 31 (2013) 6122–6128 6125
Table 2
Study population descriptives for cases and controls.
Case (n=84) Control (n=198) Total (n=282) p-Value
n % n % n %
Health authority
Fraser 15 17.9 89 44.9 104 36.9a 0.000
Vancouver coastal 38 45.2 68 34.3 106 37.6
Vancouver island 31 36.9 41 20.7 72 25.5
Long term care facility
Yes 54 64.3 106 53.5 160 56.7 0.096
No 30 35.7 92 46.5 122 43.3
Gender
Males 31 36.9 65 32.8 96 34.0 0.509
Females 53 63.1 133 67.2 186 66.0
Age groups
<75 11 13.1 41 20.7 52 18.4 0.066
75–84 25 29.8 73 36.9 98 34.8
85+ 48 57.1 84 42.4 132 46.8
Chronic disease
Yes 71 84.5 179 90.4 250 88.7 0.155
No 13 15.5 19 9.6 32 11.3
Respiratory chronic condition
Yes 26 31.0 59 29.8 85 30.1 0.847
No 58 69.0 139 70.2 197 69.9
Cardiac chronic condition
Yes 58 69.0 145 73.2 203 72.0 0.474
No 26 31.0 53 26.8 79 28.0
Neurological chronic condition
Yes 36 42.9 74 37.4 110 39.0 0.388
No 48 57.1 124 62.6 172 61.0
Hospitalized
Yes 23 27.4 60 30.3 83 29.4 0.622
No 61 72.6 138 69.7 199 70.6
Vaccinated
Yes 65 77.4 162 81.8 227 80.5 0.390
No 19 22.6 36 18.2 55 19.5
Vaccine type
ATIV 42 50.0 123 62.1 165 58.5 0.160
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Unvaccinated 19 22.6 36
a p-Value <0.05, based on a Chi-squared test.
2 (14%) were inﬂuenza B, 1 (1%) was H1N1 and 71 (85%) were
3N2.
T-test and Chi-squared analyses indicated that the cases and
ontrols differed signiﬁcantly only in their age and their health
uthority (2(2,282) 19.66, p< .05). Compared to the controls, cases
ere slightly older (84.8 vs. 82.2, p=0.018). A larger percentage of
ases were Vancouver Coastal and Vancouver Island, while a large
ercentage of controls were from Fraser. No other differences were
ound among cases and controls (Table 2). The type speciﬁc results
ere similar for H3N2 and were not possible for the other types
ue to low numbers.
.2. Univariate analysis
The vaccine effectiveness of any vaccine was 24% (CI: −42% to
9%NS). TheVEof ATIV for thewhole populationwas 35% (CI:−25%
o 81% p=0.2) and for TIV was −12%.
In the analysis of baseline characteristics tested as potential
onfounding or risk factors, only age and health authority were
igniﬁcantly related to the outcome variable (Table 3). Compared
o participants under 75 years of age, those 85 years of age or older
ere 2.1 times more likely to have laboratory conﬁrmed inﬂuenza.
A subgroup analysis of study participants not in a long-termare facility (n=122) showed a signiﬁcant vaccine effectiveness of
3% (p=0.023) for the receipt of any vaccine, with a ATIV vaccine
ffectiveness of 73% (CI: 14–92% p=0.03). The vaccine effectiveness
f TIV in this group was 42% but was not signiﬁcant (p=0.30).19.7 62 22.0
18.2 55 19.5
3.3. Multivariate analysis
Logistic regression was used to assess the effectiveness of
vaccination statuswhile controlling for age, sex, long term care res-
idency, chronic conditions, health authority, and week of testing.
The analysiswas completed using the total samplewith a subgroup
analysis completed by long term residency status and by type of
inﬂuenza. None of the speciﬁc chronic conditions or hospitaliza-
tion signiﬁcantly contributed to the model and these were thus not
included in the ﬁnal model. While age was not found to be signif-
icant in the model, the preferential administration of the vaccine
was based on age, and for this reason was included in the model.
We also tested for a possible interaction effect between vaccina-
tion and hospitalization, vaccination and long term care residency,
long term care residency and age, and vaccination and age. None
of the interactions were found to be signiﬁcantly related to the
outcome measure and, therefore, these interaction terms were
removed from the ﬁnal models to retain degrees of freedom. No
effect modiﬁers or multi-collinearity was observed.
Table 4 presents the results for the ﬁnal multivariate logis-
tic regression model. When controlling for the variables indicated
above, ATIV had a vaccine effectiveness of 58% (CI: 5–82, p<0.04)
and TIV was ineffective. Other signiﬁcant factors in the model were
residence in a long term care facility and health authority. Sub-
stituting age as a grouped variable in the model did not alter VE
calculations.
Similar resultswere foundamongnon-long-termcare residents.
When controlling for age, gender, presence of a chronic condition,
health authority, and week of testing those vaccinated with ATIV
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Table 3
Univariate logistic regression analysis. Crude odds ratio for contracting the season
ﬂu according to binomal logistic regression.
OD L 95%CI H 95%CI p-Value
Health authority
Fraser –
Vancouver coastal 3.316 1.687 6.518 0.001
Vancouver island 4.486 2.186 9.207 0.000
Long term care facility
Yes 1.562 0.923 2.645 0.097
Gender
Males –
Females 0.836 0.490 1.424 0.509
Age 1.038 1.006 1.070 0.020
Age groups
<75 –
75–84 1.276 0.570 2.857 0.553
85+ 2.130 1.002 4.527 0.049
Chronic disease
Yes 0.580 0.272 1.236 0.158
Respiratory chronic condition
Yes 1.056 0.607 1.838 0.847
Cardiac chronic condition
Yes 0.815 0.466 1.427 0.475
Neurological chronic condition
Yes 1.257 0.748 2.112 0.388
Hospitalized
Yes 0.867 0.492 1.529 0.623
Vaccinated
Yes 0.760 0.407 1.422 0.391
Vaccine type
Unvaccinated –
w
u
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Table 5
Relative vaccine effectiveness multivariate analysis. Adjusted odds ratio for con-
tracting the seasonal ﬂu according to binomal logistic regression among those
vaccinated (n=227).
OD L 95%CI H 95%CI p-Value
Vaccine
TIV –
ATIV 0.37 0.14 0.96 0.040
Gender
Males –
Females 0.61 0.30 1.22 0.159
Age 1.01 0.96 1.06 0.696
Long term care facility
No –
Yes 5.38 2.08 13.93 0.001
Chronic disease
No –
Yes 0.28 0.10 0.82 0.021
Health authority
FH –
VCH 4.92 2.10 11.56 0.000ATIV 0.647 0.335 1.248 0.194
TIV 1.117 0.524 2.384 0.774
ere less likely to test positive for inﬂuenza compared to those
nvaccinated (VE of 72%, 95% CI: 2–93%, p-value =0.047) TIV was
neffective (p=0.623).
Among the vaccinated study population (n=227), the relative
E was 63% (4–86%, p=0.04) when comparing ATIV to TIV directly
see Table 5).
In summary, the VE for ATIV was 58% (5–82%, p=0.04) overall
or this study population, and 72% (2–93%, p =0.047) for non-long
erm care residents.
able 4
ultivariate analysis. Adjusted odds ratio for contracting the season ﬂu according
o binomal logistic regression.
OD L 95%CI H 95%CI p-Value
Vaccine
Unvaccinated –
ATIV 0.419 0.185 0.951 0.038
TIV 1.017 0.432 2.392 0.970
Long term care facility
No –
Yes 2.774 1.289 5.970 0.009
Gender
Males –
Females 0.721 0.394 1.320 0.289
Age 1.037 0.996 1.079 0.076
Chronic disease
No –
Yes 0.310 0.128 0.752 0.010
Health authority
Fraser –
Vancouver coastal 4.595 2.181 9.682 0.000
Vancouver island 4.906 2.058 11.700 0.000
Testing week 1.015 0.926 1.114 0.747
Vaccinateda
No –
Yes 0.620 0.301 1.274 0.193
a Replacing vaccine type in model.VIHA 5.55 1.93 16.02 0.002
Week No. 0.95 0.84 1.07 0.396
4. Discussion
In the winter of 2011–12 in British Columbia, an adjuvanted
sub-unit trivalent inﬂuenza vaccine showed superior vaccine effec-
tiveness against laboratory conﬁrmed inﬂuenza than the spilt
virion unadjuvanted vaccine.
The overall vaccine effectiveness against the elderly target pop-
ulation was low and TIV was ineffective in all groups except those
not in residential care. The superior vaccine effectiveness of the
adjuvanted vaccine was seen despite the potential for negative
confounding, in which the vaccine was being used more often in
those over 85 years of age and in those resident in long term
care facilities, settings associated with an increased likelihood of
immunosenescence [12–14]. When these factors were taken into
account inmultivariatemodels, adjuvanted vaccine had aVE of 58%
and TIV was ineffective.
The relative ineffectiveness of TIV in this population was not
surprising and had been described before [15,16]. United States
surveillance in the study year showed a drift in the circulation of
the predominant H3N2 type towards the end of the season and
TIV is known to be less effective in these conditions [17]. The
improved protection of adjuvanted vaccine across clades was pre-
viously seen in studies of H5N1 vaccines [18,19]. Clinical trials have
also shown that MF59 adjuvanted vaccines are more immunogenic
than conventional nonadjuvanted vaccines and also provide better
immunogenicity against drifted seasonal strains that are different
from the virus strains included in the vaccine [20].
While this enhanced effectiveness is demonstrated in a single
year it is unlikely to be a chance ﬁnding. A broad based compara-
tive study in Lombardi over three inﬂuenza seasons in Italy found
the risk of hospitalization for inﬂuenza or pneumonia was 25%
lower for adjuvanted vaccine relative to TIV (relative risk =0.75, CI:
0.57–0.98) [21], and a series of as yet unpublished studies looking
at immunogenicity to inﬂuenza vaccines in the elderly undertaken
at the same time as our study showed an enhanced humoral and
cellmediated response to adjuvanted vaccine over both TIV and the
intradermal TIV [22].
The study design was based on recruiting all persons over 75
years in the study area. The predominance of persons in long term
care and in hospitals and emergency rooms reﬂected testing in a
very low activity inﬂuenza season. While all family practitioners
were sent swabs and asked to test ILI patients, at no time that
winter was there a signal that inﬂuenza was circulating, and little
testing occurred in the community. It is probable that were more
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ommunity dwelling healthy elderly recruited to the study, VE
ould have been greater for both vaccines, as it was in the sub-
roup of non-LTCF residents in this study. The signiﬁcant beneﬁt
een with ATIV over TIV was enhanced by the large number of
lderly with co-morbid conditions in the study group, a situa-
ion where TIV effectiveness lessens. A randomized controlled trial
ith anAS03-adjuvanted vaccine in older ambulatory adults,while
howing a lesser difference thanwe found, did have an incremental
fﬁcacy of 22% over plain TIV against H3N2 in a post hoc analysis
23].
Our study allocated controls using elderly with ILI who were
nﬂuenza negative on laboratory testing. This use of a “test neg-
tive” design for a community based study of inﬂuenza VE was
odelled by Orenstein and found to provide a reliable estimate
f odds ratio from a case control study when a test with a high
peciﬁcity is used [24]. The methodology is also consistent with
he recommendations of the European CDC for vaccine effective-
ess studies [25]. It has previously been used in Canadian settings
o assess the pandemic vaccine effectiveness [26].
Vaccine unavailability at times during the vaccination period
ed to some elderly and in long term care receiving TIV in the ‘adju-
anted area’. This did not affect the study outcomes. Similarly, an
bsence of TIV towards the end of the vaccination period led to
ome of those under 75 years receiving adjuvanted vaccine. This
nabled some assessment of VE in younger groups but the num-
ers were small. A second year of the study is planned to include a
roader age range and an increased focus on community dwelling
lderly.
Adjuvanted vaccine is not a panacea in elderly persons with
mmunosenescence, with a standardized VE in this study of about
0%. However, TIV was ineffective in the same group this year and
djuvanted vaccine appeared to be a signiﬁcant improvement on
he protection available against the known hospitalizations and
eath in this group.
.1. Limitations
An observational study design was used. Which vaccine was
dministeredwasdeterminedbyexternal factors suchas thehealth
uthority and the availability of vaccine. However, the evaluation
as conducted by the health authorities themselves, and while it
ould have been unethical to randomize a control group, when
ublic health policy is for all in this age group to be vaccinated,
control group “self-selected” by not being vaccinated. There is a
otential for the presence of a healthy vaccine effect, where those
hat are more health conscious and have a healthier lifestyle are
ore likely to be vaccinated.However, this bias isminimized in this
tudy population; among elderly, those with chronic conditions
ndpoorer health, aremore likely to have their health care provider
ecommend the vaccine to them. It remains possible though that
roups declining vaccination have different thresholds for seeking
are and thus being exposed to testing.
The total study subject numbers were very small due to the low
evel of inﬂuenza activity in the community that year. Repeated
tudies in subsequent years are necessary to conﬁrm ﬁndings and
ook for potential strain variation not assessable due to a relatively
omogenous strain year. Similarly, low numbers prevented the
valuation of protection against hospitalization, another important
ublic health outcome.
Blinding of interviewers of the classiﬁcation of the study par-
icipant (i.e. case vs. control) was not possible as the interviews
onducted were a little different. However, the key extracted infor-
ationwas thepresence and typeof vaccinationand this is unlikely
o have been subject to non-blinding bias by interviewers.
Further limitations of this study were that the analysis did
ot control for socio-economic status or smoking status other
[e 31 (2013) 6122–6128 6127
potential confounders. In mitigation, unpublished data from local
studies show smoking rates of only 3% in this group, almost cer-
tainly due to a mortality factor among smokers in the very elderly.
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